High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies

The hypomethylating agents (HMAs) azacytidine (AZA) and decitabine (DAC) are usually administered after the failure of erythropoietin-stimulating agents for lower-risk myelodysplastic syndromes (LR-MDS). However, it is unclear whether one of these HMAs has superior efficacy and safety. This was inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Ziqi, Han, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109092/
https://www.ncbi.nlm.nih.gov/pubmed/33818418
http://dx.doi.org/10.18632/aging.202767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109092/
https://www.ncbi.nlm.nih.gov/pubmed/33818418
http://dx.doi.org/10.18632/aging.202767

Ejemplares similares